{
    "medicine_id": "eaa8643904d718ed25c57af8d9888932fd3e00eb",
    "platform_id": "DB00385",
    "metadata": {
        "name": "Valrubicin Intravesical Solution 40 mg 1mL Solution concentrate",
        "composition": "40 mg 1mL Valrubicin",
        "clinical_particulars": {
            "therapeutic_indications": "For the treatment of cancer of the bladder",
            "contraindications": {
                "disease": "The primary anticipated complications of overdosage associated with intravesical administration would be consistent with irritable bladder symptoms Myelosuppression is possible if valrubicin is inadvertently administered systemically or if significant systemic exposure occurs following intravesical administration e g in patients with bladder rupture perforation The maximum tolerated dose in humans by either intraperitoneal or intravenous administration is 600 mg m sup 2 sup",
                "pregnancy": "NA",
                "machine_ops": "NA",
                "pharmacodynamics": "Valrubicin is an anticancer agent",
                "excipients": "NA",
                "incompatibilities": [
                    {
                        "drugbank-id": "DB00012",
                        "description": "The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Valrubicin"
                    },
                    {
                        "drugbank-id": "DB00016",
                        "description": "The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Valrubicin"
                    },
                    {
                        "drugbank-id": "DB08894",
                        "description": "The risk or severity of Thrombosis can be increased when Peginesatide is combined with Valrubicin"
                    },
                    {
                        "drugbank-id": "DB09107",
                        "description": "The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol epoetin beta is combined with Valrubicin"
                    },
                    {
                        "drugbank-id": "DB00072",
                        "description": "The risk or severity of cardiotoxicity can be increased when Trastuzumab is combined with Valrubicin"
                    },
                    {
                        "drugbank-id": "DB14967",
                        "description": "The risk or severity of cardiotoxicity can be increased when Margetuximab is combined with Valrubicin"
                    }
                ]
            }
        },
        "revision_date": "2023-05-14"
    }
}